Supplementary Figure S2 from MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors

Supplementary Figure S2. In vitro characterization of MEN1309/OBT076. A) ELISA assay showed that both the unconjugated and DM4-conjugated antibodies were able to bind FcγRIIIA with the same affinity (n=2). B) FACS binding experiment on THP-1 cell line, performed by titrating unlabeled antibody with a constant amount of labelled antibody, showed high binding affinity of MBH1309/OBT076 to CD205 expressed on the cell surface with no affinity loss after conjugation (N=2). C) In vitro ADCC bioluminescence assay showed that, despite the ability to bind FcγRIIIA, MBH1309/OBT076 didn't induce any ADCC response. D) In vitro CDC assay on Raji cancer cell lines showed no CDC activity of MBH1309/OBT076 when incubated with purified human complement. On the contrary, Rituximab (used as positive control), showed a strong induction of CDC activity.